German biotech BioNTech AG has added Sanofi as a strategic investor as the French pharma giant takes an €80m equity stake and agrees to extend a 2015 research collaboration between the two companies. Concomitantly, the partners have agreed to co-develop the first cancer immunotherapy candidate from the collaboration that is entering clinical testing in multiple solid tumors.
In the original deal (Also see "Sanofi Hopes BioNTech Pact Can Help Reboot Cancer Prospects" - Scrip, 3 November,...